Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Bluemn, Eric G., Coleman, Ilsa M., Lucas, Jared M., Coleman, Roger T., Hernandez-Lopez, Susana, Tharakan, Robin, Bianchi-Frias, Daniella, Dumpit, Ruth F. +19 more·2017·Cancer Cell

DOI 10.1016/j.ccell.2017.09.003

Cited by (744)

Items 401–500 of 744

Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness
Elena Poli, Vanessa Barbon, Silvia Lucchetta, Manuela Cattelan, Luisa Santoro, Angelica Zin, Giuseppe Maria Milano, Ilaria Zanetti, Gianni Bisogno, Paolo Bonvini · 2022 · OncoImmunology
Molecular Mechanisms of Castrate-Resistant Prostate Cancer
Srinath Kotamarti, Andrew J. Armstrong, Thomas James Polascik, Judd W. Moul · 2022 · Urologic Clinics of North America
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
David R. Wise, Russell Kent Pachynski, Samuel Ray Denmeade, Rahul Raj Aggarwal, Jiehui Deng, Victor Adorno Febles, Arjun Vasant Balar, Minas Platon Economides, Cynthia A. Loomis, Shanmugapriya Selvaraj et al. · 2024 · Prostate Cancer and Prostatic Diseases
Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models
Syeda Afshan, Yu Gang Kim, Jesse Mattsson, Malin Åkerfelt, Pirkko L. Härkönen, Martin Baumgartner, Matthias Nees · 2024 · Cancer Medicine
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study
Rong Huang, Chunlai Zuo, Christine E. Mona, Adrien Holzgreve, Colm M. Morrissey, Peter S. Nelson, Lauren Brady, Lawrence D. True, Anthony E. JR. Sisk, Johannes Czernin et al. · 2024 · Journal of Nuclear Medicine
Triplet therapy for metastatic castration‐sensitive prostate cancer: Rationale and clinical evidence
Hiroyoshi Suzuki, Shusuke Akamatsu, Masaki Shiota, Haruka Kakiuchi, Takahiro Kimura · 2024 · International Journal of Urology
Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study
Tingwei Zhang, Beihe Wang, Wei Yu, Hualei Gan, Bangwei Fang, Xiaomeng Li, Junlong Wu, Xiaojie Bian, Jianfei Wang, Stephen J. Freedland et al. · 2025 · Cell Reports Medicine
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver
Dean G. Tang · 2025 · Journal of Clinical Investigation
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
Katherine C. Murphy, Kelly D. DeMarco, Lin Zhou, Jessica Peura, Hadiya K. Giwa, Yvette Lopez-Diaz, Yu-Jui Ho, Junhui Li, Shi Bai, Karl J. Simin et al. · 2025 · Cancer Research
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature
Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman, Holly M. Nguyen, Daniel Wei Lin, Eva Corey, Peter S. Nelson, Colm M. Morrissey · 2021 · PLoS ONE
IL1β Expression Driven by Androgen Receptor Absence or Inactivation Promotes Prostate Cancer Bone Metastasis
Anthony DiNatale, Asurayya Worrede, Waleed Iqbal, Michael Marchioli, Allison Toth, Martin Sjöström, Xiaolin Zhu, Eva Corey, Felix Yi-Chung Feng, Wanding Zhou et al. · 2022 · Cancer Research Communications
Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer
Rashi Jindal, Abheepsa Nanda, Maalavika Pillai, Kathryn E. Ware, Divyoj Singh, Manas Sehgal, Andrew J. Armstrong, Jason A. Somarelli, Mohit Kumar Jolly · 2023 · Computational and Structural Biotechnology Journal
A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data
Juanlan Huang, Dale Liu, Jun Li, Jing Xu, Shaowei Dong, Hao Zhang · 2023 · Annals of Medicine
Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer
Nafisa Barma, Timothy Stone, Lina M. Carmona Echeverria, Susan Heavey · 2021 · Biomolecules
Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology
The AACR Pathology Task Force, Carolyn C. Compton, Angelo Michael De Marzo, Jayanta Debnath, Keith D. Eaton, Kojo S.J. Elenitoba‐Johnson, Michelangelo Fiorentino, Christopher Alexander French, Thomas J. Fuchs, Felice Giangaspero et al. · 2021 · Clinical Cancer Research
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy
Elizabeth Chien Hern Liow, Nicholas Howard, Chol-Hee Jung, Bernard J. Pope, Bethany K. Campbell, Anne Nguyen, Michael Kerger, Jonathan B. Ruddle, Angelyn Anton, Benjamin Thomas et al. · 2022 · Clinical Genitourinary Cancer
Bacterial RNA virus MS2 exposure increases the expression of cancer progression genes in the LNCaP prostate cancer cell line
Swapnil Ganesh Sanmukh, Nilton Barreto dos Santos, Caroline N. Barquilha, Márcio de Carvalho, Patricia Dos Reis, Flávia Karina Delella, Hernandes F. Carvalho, Dorota Latek, Tamás Fehér, Sérgio Luís Felisbino · 2023 · Oncology Letters
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems
Hannah E. Bergom, Ashraf Shabaneh, Abderrahman Day, Atef Abdel-Moneem Ali, Ella Boytim, Sydney Tape, John R. Lozada, Xiaolei Shi, Carlos Jesus Perez Kerkvliet, Sean Thomas McSweeney et al. · 2023 · Communications Biology
High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer
Lei Chen, Yiyi Ji, Ang Li, Bo Liu, Kai Shen, Ruopeng Su, Zehua Ma, Weiwei Zhang, Qi Wang, Yinjie Zhu et al. · 2023 · Frontiers in Oncology
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy
Kim van der Zande, Rebecca D. Louhanepessy, Paul Hamberg, Sb Ras, Jeantine M. de Feijter, Vincent Olaf Dezentjé, Annegien Broeks, Sten Cornelissen, Aart Beeker, Vincent van der Noort et al. · 2024 · Clinical Genitourinary Cancer
Multi-omics analysis constructs a novel neuroendocrine prostate cancer classifier and classification system
Junxiao Shen, Luyuan Lu, Zhijie Chen, Wei Guo, Shuwen Wang, Ziqiao Liu, Xuke Gong, Yiming Qi, Ruyi Jin, Cheng Zhang · 2025 · Scientific Reports
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer
Karl Semaan, Rashad Nawfal, John Canniff, Hunter Savignano, Ji-Heui Seo, Stephanie Siegmund, Sarah J. Wu, Julia K. Rotow, Gwo‐Shu Mary Lee, Razane El Hajj Chehade et al. · 2025 · npj Precision Oncology
Transcriptional profiles of circulating tumor cells reflect heterogeneity and treatment resistance in advanced prostate cancer
Lina Bergmann, Sarah Greimeier, Sabine Riethdorf, Tina Rohlfing, Moritz Kaune, Tobias Busenbender, Nadja Strewinsky, Sergey A. Dyshlovoy, Simon Andreas Joosse, Sven Peine et al. · 2025 · Journal of Experimental & Clinical Cancer Research
Intratumor δ-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression
Mingchuan Li, Jongdee Nopparat, Byron J. Aguilar, Yanhua Chen, Jiao Zhang, Jie Du, Xin Ai, Yong Luo, Yongguang Jiang, Christi Boykin et al. · 2020 · Oncogene
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials
Ke Chen, Xiaoping Zhang, Qi Cao, Peng Bai, Deyao Shi, Jiali Liao, Hangchuan Shi, Yifei Xing · 2020 · Journal of Cancer Research and Therapeutics
Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics
Mayuko Kanayama, Jun Luo · 2021 · International Journal of Molecular Sciences
AR independent anticancer potential of enza against prostate cancer
Abu Baker, Asad Syed, Sana Iram, Abdallah Mohamed Elgorban, Helal F. Al-Harthi, Salim Saleh Al-Rejaie, Jihoe Kim, Mohd Shariq Khan · 2022 · Colloids and Surfaces A Physicochemical and Engineering Aspects
PGC1 alpha coactivates ERG fusion to drive antioxidant target genes under metabolic stress
Aiindrila Dhara, Imlimaong Aier, Ankush Paladhi, Pritish Kumar Varadwaj, Sumit Kumar Hira, Nirmalya Sen · 2022 · Communications Biology
Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging
Courtney Yong, Devon Lyle Moose, Nadine Bannick, Wade R. Gutierrez, Marion Vanneste, Robert Svensson, Patrick John Breheny, James A. Brown, Rebecca D. Dodd, Michael B. Cohen et al. · 2020 · PLoS ONE
The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype
Patrick B. Thomas, Penny L. Jeffery, Manuel David Gahete, Eliza Whiteside, Carina Walpole, Michelle Maugham, Lidija Jovanovic, Jennifer H. Gunter, Elizabeth D. Williams, Colleen C. Nelson et al. · 2021 · PeerJ
The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants
Hong Wang, Zhe Chang, Guodi Cai, Ping Yang, Jiang-he Chen, Shan-shu Yang, Yinfeng Guo, Mingyu Wang, Xuehua Zheng, Jinping Lei et al. · 2021 · Acta Pharmacologica Sinica
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
Ritika Tiwari, Nishat Manzar, Vipul Bhatia, Anjali Yadav, Shannon L. Carskadon, Nilesh Gupta, Amina Zoubeidi, Nallasivam Palanisamy, Bushra Ateeq · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, A. Eden Cruikshank, Caroline Kikawa, Katheryn Santos, Joseph B. Hiatt, Robert D. Patton, Navonil De Sarkar, Anna C. H. Hoge et al. · 2021 · medRxiv
NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer
Jia J. Li, Alessandro Vasciaveo, Dimitrios Karagiannis, Zhen Sun, Xiao Chen, Fabio Socciarelli, Ziv Frankenstein, Min Zou, Tania Pannellini, Yu Chen et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer
Michael L. Beshiri, Brian J. Capaldo, Ross G. Lake, Anson T. Ku, Danielle N. Burner, Caitlin M. Tice, Crystal Tran, Julianna Kostas, Aian Neil Alilin, Juan-Juan Yin et al. · 2024 · Stem Cells
Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway
Vignesh Sivaganesh, Tram M. Ta, Bela Peethambaran · 2024 · International Journal of Molecular Sciences
Stromal androgen signaling governs essential niches in supporting prostate development and tumorigenesis
June‐Wha Rhee, Yao Mawulikplimi Adzavon, Zijie Sun · 2024 · Oncogene
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer
Xiaolin Zhu, Chien‐Kuang Cornelia Ding, Rahul Raj Aggarwal · 2025 · Current Oncology Reports
Depletion of Acetyl‐CoA Carboxylase 1 Facilitates Epithelial‐Mesenchymal Transition in Prostate Cancer Cells by Activating the MAPK/ERK Pathway
Jiarun Lai, Shaoyou Liu, Yupeng Chen, Jian Chen, Jinchuang Li, Zhenguo Liang, Xinyue Mei, Yuanfa Feng, Zhaodong Han, Funeng Jiang et al. · 2025 · MedComm
Racial variation in the advanced prostate cancer genome
Emily Feng, Jenny M. Vo-Phamhi, Aishwarya Subramanian, Mikhail Dias, Adam Foye, Jake Vinson, Julian C. Hong, Stephen J. Freedland, Joshi J. Alumkal, Himisha Beltran et al. · 2025 · Prostate Cancer and Prostatic Diseases
EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
Justine J. Jacobi, Kristine M. Wadosky, Neha Jaiswal, Xiaojing Zhang, Yanqing Wang, Prashant K. Singh, Jie Wang, Eduardo Cortes Gomez, Jianmin Wang, Bo Xu et al. · 2025 · Cancer Research
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules
Phillip Thienger, Irene Paassen, Xiaosai Yao, Philip D. Rubin, Marika Lehner, Nicholas Lillis, Andrej Benjak, Sagar R Shah, Alden King-Yung Leung, Simone de Brot et al. · 2026 · Cancer Research
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
Lucie Van Emmenis, Sheng‐Yu Ku, Kaitlyn M. Gayvert, Jonathan R. Branch, Nicholas J. Brady, Subhasree Basu, Mike R. Russell, Joanna Cyrta, Aram Vosoughi, Verena Wilbeth Sailer et al. · 2023 · Cancer Research Communications
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor
Anthony Turpin, Carine Delliaux, Pauline Parent, Hortense Chevalier, Carmen Escudero‐Iriarte, Franck Bonardi, Nathalie Vanpouille, Anne Flourens, Jessica Querol, Aurélien Carnot et al. · 2023 · British Journal of Cancer
Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies
Simone Weiss, Philippe Lamy, Maria Rusan, Maibritt Nørgaard, Benedicte Parm Ulhøi, Michael Knudsen, Christine Gaasdal Kassentoft, Leila Farajzadeh, Jørgen Bjerggaard Jensen, Jakob Skou Pedersen et al. · 2024 · International Journal of Cancer
Hippo signaling modulation and its biological implications in urological malignancies
Tongyu Tong, Mengjun Huang, Binyuan Yan, Bingbiao Lin, Jiaying Yu, Qiliang Teng, Peng Li, Jun Pang · 2024 · Molecular Aspects of Medicine
Identification of blood lipid markers of docetaxel treatment in prostate cancer patients
Morgan C. Finnerty, Franklin E. Leach, Yousef Zakharia, Kenneth Gerard Nepple, Michael G. Bartlett, Michael D. Henry, Brian S. Cummings · 2024 · Scientific Reports
Microtubule regulation in cancer cells
Alexandre Matov · 2026 · Frontiers in Cell and Developmental Biology
Mild photothermal therapy-enhanced nano-ferroptosis inducer for potent treatment of advanced prostate cancer
Xiao Jie Hu, Fei Li, Xin-Hang Qian, Yusen Zhang, Shuai Ke, Yunxia Jin, Shuai Yuan, Yuanyuan Zhang, Rui Li, Lei Cao et al. · 2025 · Nano Research
Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer
Jordan E. Vellky, Tyler M. Bauman, Emily A. Ricke, Wei Huang, William A. Ricke · 2019 · The Prostate
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James Robert Bischoff, Georges Habineza et al. · 2021 · Molecular Cancer Therapeutics
There are gremlins in prostate cancer
Laura A. Sena, William Nathaniel Brennen, John T. Isaacs · 2022 · Nature Cancer
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer
Sean Thomas McSweeney, Hannah E. Bergom, Anna E. Prizment, Susan Halabi, Nima Sharifi, Charles J. Ryan, Justin H. Hwang · 2022 · Endocrine Oncology
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones
Minas Sakellakis, Andrew Warren Hahn, Sumankalai Ramachandran, Miao Zhang, Anh G. Hoang, Jian H. Song, Jingjing Liu, Feng Wang, Hirak S. Basu, Peter Sheperd et al. · 2022 · Prostate Cancer and Prostatic Diseases
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer
Song Yi Bae, Hannah E. Bergom, Abderrahman Day, Joseph T. Greene, Zoi E. Sychev, Gabrianne Larson, Eva Corey, Stephen R. Plymate, Tanya S. Freedman, Justin H. Hwang et al. · 2023 · Frontiers in Endocrinology
Involvement of the MEN1 Gene in Hormone-Related Cancers: Clues from Molecular Studies, Mouse Models, and Patient Investigations
Razan Abou Ziki, Yakun Luo, Virginie Vlaeminck‐Guillem, Muriel Le Romancer, Chang Xian Zhang · 2020 · Endocrines
ONECUT2 is a novel target for treatment of castration-resistant prostate cancer
Tejashree Joglekar, Jianqing Lin, Maho Shibata · 2020 · Expert Opinion on Therapeutic Targets
IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer
Yetunde Oyende, Luke J. Taus, Alessandro Fatatis · 2025 · Cancers
Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer
Yujun Shuai, Haojie Huang · 2025 · Journal of the National Cancer Center
Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer
Nicolò Formaggio, Jacopo Sgrignani, Gayathri Thillaiyampalam, Claudio Lorenzi, Giada Andrea Cassanmagnago, Marco Coazzoli, Federico Costanzo, Yanick Uebelhart, Daniela Bossi, Diego Camuzi Cassiano et al. · 2025 · Cell Reports
Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review
Olga Kouroukli, Vasiliki Bravou, Konstantinos Giannitsas, Vassiliki Tzelepi · 2024 · Cancers
Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance
Anmbreen Jamroze, Xiaozhuo Liu, Dean G. Tang · 2024 · Cancer Heterogeneity and Plasticity
Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes
Hannah E. Bergom, Ella Boytim, Sean Thomas McSweeney, Negar Sadeghipour, Andrew Elliott, Rachel Passow, Eamon Toye, Xiuxiu Li, Pornlada Likasitwatanakul, Daniel M. Geynisman et al. · 2024 · JCI Insight
SLX4IP Promotes Telomere Maintenance in Androgen Receptor–Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization
Tawna L. Mangosh, Wisam N. Awadallah, Magdalena M. Grabowska, Derek J. Taylor · 2020 · Molecular Cancer Research
ANO7 African-ancestral genomic diversity and advanced prostate cancer
Jue Jiang, Pamela X. Y. Soh, Shingai Bertrand Angelo Mutambirwa, Riana M. S. Bornman, Christopher A. Haiman, Vanessa M. Hayes, Weerachai Jaratlerdsiri · 2023 · Prostate Cancer and Prostatic Diseases
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
Michelle Shen, Shiqin Liu, Angus Martin Shaw Toland, En‐Chi Hsu, Alifiani Bonita Hartono, Busola Ruth Alabi, Merve Aslan, Holly M. Nguyen, Conner J. Sessions, Rosalie Nolley et al. · 2023 · British Journal of Cancer
The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care
Kunal K. Sindhu, Zachary S. Dovey, Marcher Thompson, Anthony D. Nehlsen, Karin A. Skalina, Beata Małachowska, Shaakir Hasan, Chandan Guha, Justin Tang, Lucas Resende Salgado · 2024 · BJUI Compass
Overexpression of REST Represses the Epithelial–Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells
Sebastián Indo, Octavio Orellana‐Serradell, María José Torres, Enrique A. Castellón, Héctor R. Contreras · 2024 · International Journal of Molecular Sciences
GRK2 enforces androgen receptor dependence in the prostate and prostate tumors
Adam J. Adler, Payal Mittal, Adam T. Hagymasi, Antoine Ménoret, Chen Shen, Federica Agliano, Kyle Wright, James J. Grady, Chia‐Ling Kuo, Enrique Ballesteros et al. · 2020 · Oncogene
Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer
Benedito A. Carneiro, Tamara Levin Lotan, André Oliveira Souza, Rahul Raj Aggarwal · 2020 · American Society of Clinical Oncology Educational Book
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
Kristine M. Wadosky, Yanqing Wang, Xiaojing Zhang, David W. Goodrich · 2019 · Journal of Visualized Experiments
Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling
Samir Zaidi, Jimmy L. Zhao, Joseph Minhow Chan, Martine P. Roudier, Kristine M. Wadosky, Anuradha Gopalan, Wouter R. Karthaus, Jungmin Choi, Kayla E. Lawrence, Ojasvi Chaudhary et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype
Sumer Jasmine, Rajendra Kumar, Sunghyun Kim, Timothy E. G. Krueger, Ilsa M. Coleman, Susan L. Dalrymple, Lizamma Antony, D. Marc Rosen, Brian P. Hanratty, Radhika A. Patel et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Systems-level liquid biopsy in advanced prostate cancer
Jacque A. Lyman, Scott M. Dehm · 2025 · Endocrine Related Cancer
Clinical and Genomic Features of Androgen Indifferent Prostate Cancer
Jack Masur, Aakrosh Ratan, Krzysztof Wierbiłowicz, Adanma Ayanambakkam, Michelle L. Churchman, Laura S Graham, George Daniel Grass, Sumati V. Gupta, Sean Q. Kern, Jennifer M. King et al. · 2025 · International Journal of Molecular Sciences
An integrated proteomic portrait of prostate cancer progression
Jichang Zhang, Keith D. Rivera, Daniela Bossi, Federico Gianfanti, Simone Nicastri, Diana Bianca Rocha Gomes, Milos Matkovic, Marco Coazzoli, Simone Mosole, Federico Costanzo et al. · 2025 · Cell Reports
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
Bilal Ashraf, Jane McKenzie, Andrew J. Armstrong · 2025 · Prostate Cancer and Prostatic Diseases
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer
Stuthi Pavani Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran, Robert A. Parise, Robert R. Bies, David I. Quinn, Kristopher M. Attwood et al. · 2025 · Cancer Chemotherapy and Pharmacology
Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer
Betul Ersoy-Fazlioglu, Shreyas Lingadahalli, Umut Berkay Altıntaş, Ahmet Cingöz, Emirhan Tekoglu, Ivan Pak Lok Yu, Ugur Meric Dikbas, Olka Missaghimamaghani, Kerim Yavuz, Hans H. Adomat et al. · 2025 · Proceedings of the National Academy of Sciences
Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
Alice Bernard‐Tessier, Himisha Beltran · 2026 · Journal of Clinical Investigation
Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer
Hannah Palmer, Mhairi Nimick, Aloran Mazumder, Sébastien Taurin, Zohaib Rana, Rhonda J. Rosengren · 2022 · Biomedicines
Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer
Zhuo Huang, Ying Tang, Yuyan Wei, Jingyu Qian, Yifan Kang, Duohao Wang, Miao Xu, Ling Nie, Xueqin Chen, Ni Chen et al. · 2023 · Journal of Clinical Medicine
Insight into prostate cancer osteolytic metastasis by RelB coordination of IL‐8 and S100A4
Wenbo Sun, Kenny Xu, Xiao Li, Peipei Qian, Fan Xu, Yanyan Zhang, Xiumei Wang, Zhi Xiong Xu, Jiaji Ding, Xinyu Xu et al. · 2024 · Clinical and Translational Medicine
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit
Ilya S. Senatorov, Joel Bowman, Keith H. Jansson, Aian Neil Alilin, Brian J. Capaldo, Ross G. Lake, Morgan Riba, Yasmine C. Abbey, Crystal G. McKnight, Xiaohu Zhang et al. · 2024 · Cell Reports Medicine
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Marina Nasrin Sharifi, Eric Li-Len Feng, Nicholas Robert Rydzewski, Amy K. Taylor, Jamie M. Sperger, Yue Shi, Kyle T. Helzer, Matthew L. Bootsma, Viridiana Carreno, Alex H. Chang et al. · 2025 · Molecular Oncology
Computational analysis of treatment resistant cancer cells
Alexandre Matov · 2026 · Frontiers in Cell and Developmental Biology
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
Juho Jasu, Teemu T. Tolonen, Emmanuel S. Antonarakis, Himisha Beltran, Susan Halabi, Mario A. Eisenberger, Michael Anthony Carducci, Yohann Loriot, Kim Van der Eecken, Martijn P. Lolkema et al. · 2021 · European Urology Open Science
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry
Brendon M. Patierno, Wen‐Chi Foo, Tyler A. Allen, Jason A. Somarelli, Kathryn E. Ware, Santosh K. Gupta, Sandra S. Wise, John Pierce Wise, Xiaodi Qin, Dadong Zhang et al. · 2021 · Prostate Cancer and Prostatic Diseases
Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities
Gal Rinott Mizrahi, Isabella S. C. Williams, Arun Azad, Nathan Lawrentschuk · 2022 · Current Opinion in Urology
Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer
Reeree Lee, Han‐Byoel Lee, Jin Chul Paeng, Hongyoon Choi, Wonseok Whi, Wonshik Han, Dong-Young Noh, Ju Won Seok, Keon Wook Kang, Gi Jeong Cheon · 2022 · PLoS ONE
Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancer
Amanda Broderick, Matthew Labriola, Neal D. Shore, Andrew J. Armstrong · 2023 · BMJ Case Reports
Integrating intracellular and extracellular proteomic profiling for in‐depth investigations of cellular communication in a model of prostate cancer
Hannah N. Miles, Devin Tomlin, William A. Ricke, Lingjun Li · 2023 · PROTEOMICS
Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer
Louise Kathleen Kostos, Heidi Fettke, Edmond M. Kwan, Arun Azad · 2023 · Société Internationale d’Urologie Journal
Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration‐resistant prostate cancer: Real‐world experience in the Southeast Asian cohort
Jasmine Lim, Akara Amantakul, Nisha Mohd Shariff, Bannakij Lojanapiwat, Adlinda Alip, Teng Aik Ong, Shankaran Thevarajah, Firdaus Ahmayuddin, Adeline Mathew, Supon Sriplakich et al. · 2020 · Cancer Medicine
Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilities
Fanying Tang, Shangqian Wang, Chen Khuan Wong, Cindy J. Lee, Sandra M. Cohen, Jane Park, Corinne E. Hill, Kenneth Eng, Rohan Bareja, Teng Han et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
The molecular determinants of phenotypic plasticity in homeostasis and neoplasia
Bradley Balk, David W. Goodrich · 2024 · Cancer Heterogeneity and Plasticity
ACACA depletion activates the cPLA2–arachidonic acid–NF-κB axis to drive inflammatory reprogramming in androgen receptor-independent prostate cancer
Shaoyou Liu, Yupeng Chen, Jian Chen, Jinchuang Li, Zhenguo Liang, Xinyue Mei, Yuanfa Feng, Zhaodong Han, Funeng Jiang, Yongding Wu et al. · 2025 · Cell Communication and Signaling
Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis
Jeanne Maria Dsouza, Erolcan Sayar, Michael Thomas Schweizer, Stephanie A. Harmon, Colm M. Morrissey, Himisha Beltran, Peter S. Nelson, Liang Cheng C, Chien‐Kuang Cornelia Ding, Michael C. Haffner · 2025 · Histopathology
Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer
Ryuta Watanabe, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika, Michael C. Haffner, Peter S. Nelson · 2026 · Urologic Oncology Seminars and Original Investigations
The Impact of Doxycycline as an Adjunctive Therapy on Prostate-Specific Antigen, Quality of Life, and Cognitive Function in Metastatic Prostate Cancer Patients: A Phase II Randomized Controlled Trial
José Guzmán-Esquivel, Hossana S. Garcia-Garcia, Gustavo A. Hernández‐Fuentes, Jesús Venegas-Ramírez, Carlos D. Barajas-Mejía, Idalia Garza Veloz, Margarita L. Martínez‐Fierro, Nancy E. Magaña-Vergara, José Alejandro Guzmán-Solórzano, Patricia Calvo-Soto et al. · 2025 · Pharmaceutics